Package Leaflet: Information for the Patient
Tigecycline Noridem 50 mg powder for solution for infusion EFG
Tigecycline Noridem is an antibiotic of the glycylcycline group that works by blocking the growth of the bacteria that causes the infection.
|
Your doctor has prescribed this medicine because you or your child is at least 8 years old and has one of the following types of severe infections:
Tigecycline is only used when your doctor considers that other alternative antibiotics are not suitable.
Talk to your doctor or nurse before taking tigecycline:
This medicine should not be used in children under 8 years of age due to the lack of safety and efficacy data in this age group and because it may cause permanent dental defects, such as staining of developing teeth.
Tell your doctor if you are using, have recently used, or might use any other medicines.
Tigecycline may prolong certain tests that measure if your blood clots properly. It is essential that you inform your doctor if you are taking certain medications to prevent excessive blood clotting (called anticoagulants). If so, your doctor will closely monitor you.
Tigecycline may increase the effect of medicines used to suppress the immune system (such as tacrolimus or cyclosporin). It is essential that you inform your doctor if you are taking these medicines so that you can be closely monitored.
Tigecycline may harm the fetus. If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor before using tigecycline.
It is not known if tigecycline passes into breast milk. Consult your doctor before starting breastfeeding.
Tigecycline may cause side effects such as dizziness. This may reduce your ability to drive or use machines.
This medicine contains less than 1 mmol of sodium (23 mg) per vial; it is essentially "sodium-free".
This medicine must be administered by a doctor or nurse.
The recommended dose of Tigecycline Noridem in adults is an initial dose of 100 mg, followed by 50 mg every 12 hours. These doses are administered intravenously (directly into the bloodstream) over a period of 30 to 60 minutes.
Use in children and adolescents
The normal treatment duration is 5 to 14 days. Your doctor will decide the appropriate treatment duration for you.
If you think you may have received more doses of tigecycline than you should, inform your doctor or nurse immediately.
If you are concerned about missing a dose, inform your doctor or nurse immediately.
If you have any further questions about the use of this medicine, ask your doctor or nurse.
Like all medicines, this product can cause side effects, although not everybody gets them.
Pseudomembranous colitis (swelling or inflammation of the colon) can occur with most antibiotics, including tigecycline. Pseudomembranous colitis consists of severe, persistent, or bloody diarrhea associated with abdominal pain or fever, which can be a symptom of severe intestinal inflammation that can occur during or after treatment.
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Side effects with frequency not known (frequency cannot be estimated from available data):
If you experience any side effects, talk to your doctor or nurse, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines Agency's website, www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the vial and carton after "EXP". The expiry date is the last day of the month stated.
Store below 30°C.
After reconstitution:
Once the powder has been reconstituted, it must be used immediately.
After dilution:
Physical and chemical stability has been demonstrated during use after reconstitution and immediate dilution in the bag or other suitable infusion container (e.g., glass bottle):
From a microbiological point of view, the product should be used immediately. If not used immediately, the in-use storage times and conditions are the responsibility of the user and normally should not exceed 24 hours at 2°C-8°C, unless the dilution has been made in controlled and validated aseptic conditions.
The Tigecycline Noridem solution should have a yellow to orange color after dissolution; if not, it should be discarded immediately.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Tigecycline Noridem
Tigecycline Noridem is supplied as a powder for solution for infusion in 6 ml clear glass type I vials with gray bromobutyl rubber stoppers, aluminum seals, and removable yellow polypropylene caps that contain orange powder before dilution.
This medicine is marketed in packs of 1 and 10 vials.
Not all pack sizes may be marketed.
Marketing authorization holder
Noridem Enterprises Ltd.
Evagorou & Makariou
Mitsi Building 3, Office 115
1065 Nicosia, Cyprus
Manufacturer
DEMO S.A. PHARMACEUTICAL INDUSTRY
21st Km National Road Athens-Lamia.
14568 Greece
Phone: +30 210 8161802, Fax: +30 2108161587.
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany | Tigecyclin Noridem 50 mg Pulver zur Herstellung einer Infusionslösung |
Greece | Tigecycline/DEMO |
Ireland | Tigecycline 50 mg Powder for solution for infusion |
Italy | Tigeciclina Noridem |
Spain | Tigeciclina Noridem 50 mg Polvo para solución para perfusión EFG |
Czech Republic | Tigecycline Noridem |
Slovakia | Tigecycline Noridem 50 mg Prášok na infúzny roztok |
Hungary | Tigeciklin Noridem 50 mg Por oldatos infúzióhoz |
Romania | Tigeciclina Noridem 50 mg Pulbere pentru solutie perfuzabila |
Poland | Tigecycline Noridem |
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/
Instructions for use and handling (see also section 3.of the prospectus "How to take Tigecycline Noridem"):
The powder must be reconstituted with 5.3 ml of injectable sodium chloride solution at 9 mg/ml (0.9%), with injectable dextrose solution at 50 mg/ml (5%), or with injectable Ringer's Lactate solution to achieve a concentration of 10 mg/ml of tigecycline. The vial should be gently shaken until the active ingredient is dissolved. Then, 5 ml of the reconstituted solution should be immediately withdrawn from the vial and added to a 100 ml intravenous infusion bag or other suitable infusion container (e.g., glass vial).
To obtain a dose of 100 mg, two vials should be reconstituted in a 100 ml intravenous infusion bag or other suitable infusion container (e.g., glass vial).
Note: The vial contains a 6% excess dose. Thus, 5 ml of reconstituted solution is equivalent to 50 mg of active ingredient. The reconstituted solution should be yellow to orange in color and free of visible signs of contamination; if not, the solution should be discarded. Parenteral products should be visually inspected for the presence of suspended particles or changes in particle coloration (e.g., green or black) before administration.
The ready-to-use infusion solution should be administered intravenously through a dedicated line or via a Y-line. If the same intravenous line is used for the sequential infusion of other active ingredients, the line should be flushed before and after the infusion of tigecycline with a sodium chloride solution at 9 mg/ml (0.9%) for injection or with a dextrose solution at 50 mg/ml (5%) for injection. The injection should be made with an infusion solution compatible with tigecycline and any other medication through this common line.
Compatible intravenous solutions include: injectable sodium chloride solution at 9 mg/ml (0.9%), injectable dextrose solution at 50 mg/ml (5%), and injectable Ringer's Lactate solution.
When administration is performed through a Y-line, the compatibility of tigecycline, diluted in injectable sodium chloride at 9 mg/ml (0.9%), has been verified with the following drugs or diluents: amikacin, dobutamine, dopamine hydrochloride, gentamicin, Ringer's Lactate, lidocaine hydrochloride, metoclopramide, norepinephrine, piperacillin/tazobactam, potassium chloride, propofol, theophylline, and tobramycin.
Tigecycline Noridem should not be mixed with other medications for which compatibility data are not available.
This medication should only be used for the administration of a single dose; any unused solution should be discarded.